How should I assess and manage a patient’s atherosclerotic cardiovascular disease (ASCVD) risk, including appropriate statin intensity, lifestyle modifications, and additional lipid‑lowering therapies?

ASCVD Risk Assessment and Management

Begin with calculating the 10-year ASCVD risk score in all adults aged 40-75 years, then stratify treatment based on risk category, LDL-C levels, and presence of diabetes or established ASCVD—this risk-based approach determines both statin intensity and need for additional lipid-lowering therapies. 1

Primary Prevention Strategy by Risk Category

Very High LDL-C (≥190 mg/dL)

• Initiate high-intensity statin immediately without calculating risk scores 1
• Target: ≥50% LDL-C reduction
• If LDL-C remains ≥100 mg/dL on maximally tolerated statin, add ezetimibe
• Consider PCSK9 inhibitor if LDL-C stays ≥100 mg/dL despite statin plus ezetimibe, particularly with multiple ASCVD risk factors

Diabetes (Age 40-75, LDL-C ≥70 mg/dL)

• Start moderate-intensity statin as baseline therapy 1
• Escalate to high-intensity statin (targeting ≥50% LDL-C reduction) if:
  • Age 50-75 years
  • Multiple additional risk factors present
  • Higher baseline ASCVD risk

High Risk (10-year ASCVD risk ≥20%)

• Use high-intensity statin targeting ≥50% LDL-C reduction 2, 1
• This provides maximal benefit in those with highest baseline risk
• Evidence from JUPITER trial demonstrated significant ASCVD reduction at median 1.9 years with rosuvastatin 20 mg achieving 50% LDL-C lowering 2

Intermediate Risk (10-year ASCVD risk 7.5-19.9%)

• Initiate moderate-intensity statin after clinician-patient risk discussion 1
• Target: ≥30% LDL-C reduction minimum
• Risk-enhancing factors strongly favor statin initiation and include:
  • Family history of premature ASCVD
  • Persistently elevated LDL-C ≥160 mg/dL
  • Metabolic syndrome
  • Chronic kidney disease
  • Chronic inflammatory conditions (rheumatoid arthritis, psoriasis, HIV)
  • South Asian ethnicity
  • Triglycerides ≥175 mg/dL
  • High-sensitivity CRP ≥2.0 mg/L
  • Lipoprotein(a) ≥50 mg/dL or 125 nmol/L
  • ApoB ≥130 mg/dL
  • Ankle-brachial index <0.9
  • History of preeclampsia or premature menopause

If treatment decision remains uncertain despite risk-enhancing factors, measure coronary artery calcium (CAC): 2, 1

• CAC = 0: Withhold statin, reassess in 5-10 years (except in smokers, diabetics, or strong family history)
• CAC 1-99: Initiate statin, especially if age ≥55
• CAC ≥100 or ≥75th percentile: Statin indicated

Borderline Risk (10-year ASCVD risk 5-7.5%)

• Risk-enhancing factors may justify moderate-intensity statin 2, 1
• CAC scoring particularly useful for refining decision-making in this group
• Apply same CAC thresholds as intermediate risk category

Secondary Prevention (Established ASCVD)

All patients with clinical ASCVD require high-intensity statin or maximally tolerated statin therapy targeting ≥50% LDL-C reduction. 1 The principle is simple: greater LDL-C reduction equals greater risk reduction.

Very High-Risk ASCVD Criteria

Defined as history of multiple major ASCVD events OR one major event plus multiple high-risk conditions.

Use LDL-C threshold of ≥70 mg/dL to trigger addition of non-statin therapies: 1

1. Add ezetimibe if LDL-C ≥70 mg/dL on maximally tolerated statin
2. Add PCSK9 inhibitor if LDL-C remains ≥70 mg/dL despite maximally tolerated statin plus ezetimibe
   • Note: Long-term safety beyond 3 years uncertain as of guideline publication
   • Cost-effectiveness was low at 2018 pricing

Recent evidence from 2025 demonstrates that moderate-intensity statin plus ezetimibe combination achieves comparable efficacy to high-intensity statin monotherapy with lower rates of new-onset diabetes (10.2% vs 11.9%) and drug intolerance (4.0% vs 6.7%), while achieving superior LDL-C lowering (64.8 vs 68.5 mg/dL). 3 This provides an alternative strategy for patients experiencing statin-related adverse effects.

Essential Lifestyle Modifications

Lifestyle intervention forms the foundation of all ASCVD risk reduction:

• Refer to registered dietitian nutritionist for medical nutrition therapy, particularly for complex patients and those with hypertriglyceridemia 4
• Smoking cessation (critical risk enhancer)
• Weight reduction if overweight/obese
• Mediterranean or DASH dietary pattern
• Regular aerobic physical activity
• Limit alcohol consumption
• Address metabolic syndrome components

Monitoring Strategy

Measure lipid panel 4-12 weeks after statin initiation or dose adjustment to assess:

• Adherence to therapy
• Percentage LDL-C response
• Need for intensification 1

Repeat monitoring every 3-12 months once stable, adjusting based on clinical context and treatment goals.

Critical Implementation Points

The 2026 evidence emphasizes that residual risk persists even with well-controlled LDL-C 5, requiring attention to:

• Non-HDL cholesterol and apolipoprotein B (superior risk markers on statin therapy)
• Lipoprotein(a) levels
• Triglyceride-rich lipoproteins
• Inflammatory markers (hs-CRP, IL-6)

Common pitfall: Risk-enhancing factors are highly prevalent (77% of eligible adults have ≥1 REF) 6 but inconsistently incorporated into prescribing decisions. Systematically assess and document these factors during the clinician-patient risk discussion to appropriately intensify therapy in borderline and intermediate-risk patients.

The clinician-patient risk discussion is mandatory before initiating therapy 1, covering:

• Individual major risk factors
• Calculated 10-year ASCVD risk
• Risk-enhancing factors present
• Lifestyle and statin therapy benefits
• Potential adverse effects and drug interactions
• Treatment costs
• Patient preferences and values

This shared decision-making approach ensures appropriate targeting of therapies to those most likely to benefit while respecting patient autonomy and addressing concerns about treatment burden.